Business development Archives - Pharmacelera | Pushing the limits of computational chemistry Tue, 03 Mar 2026 09:09:13 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://pharmacelera.com/wp-content/uploads/2022/04/cropped-Linkedin-avatar-32x32.png Business development Archives - Pharmacelera | Pushing the limits of computational chemistry 32 32 Freedom Space 5.0 Integrates with exaScreen® to Enable 3D Ultra-Large Virtual Screening https://pharmacelera.com/blog/partnerships/freedom-space-integrates-with-exascreen-to-enable-3d-ultra-large-virtual-screening/ Tue, 03 Mar 2026 09:06:23 +0000 https://pharmacelera.com/?p=15100 Barcelona, Spain, and Kyiv, Ukraine – March 3, 2026 – Pharmacelera, the deeptech company pushing the limits of computational technologies for drug […]

The post Freedom Space 5.0 Integrates with exaScreen® to Enable 3D Ultra-Large Virtual Screening appeared first on Pharmacelera | Pushing the limits of computational chemistry.

]]>

Barcelona, Spain, and Kyiv, Ukraine – March 3, 2026 – Pharmacelera, the deeptech company pushing the limits of computational technologies for drug discovery, and Chemspace, a global provider of small molecules and drug discovery services, today announced the launch of a powerful new joint solution that integrates the Chemspace Freedom Space 5.0 with Pharmacelera’s flagship virtual screening platform, exaScreen®. This launch provides researchers with unprecedented access to synthetically tractable chemical space combined with cutting-edge computational methods for hit discovery.

As the pharmaceutical industry increasingly turns to ultra-large libraries to identify novel hits, the challenge lies in navigating chemical diversity accurately while ensuring synthetic feasibility. The new joint solution directly addresses this challenge by combining Pharmacelera’s advanced 3D Quantum-Mechanics (QM) and Machine Learning (ML)-driven algorithms with the Chemspace Freedom Space, a curated collection of 296 billion chemically diverse and highly synthesizable compounds.

With this launch, researchers will be able to:

  • Conduct accurate and efficient virtual screening across the Chemspace Freedom Space.
  • Rapidly source and synthesize compounds for experimental validation.
  • Expand opportunities to generate novel Intellectual Property (IP) through unexplored chemical space.
  • Streamline the path from virtual prediction to real-world testing. 

"Freedom Space 5.0 was built to give researchers access to unprecedented chemical diversity while solving one of virtual screening's most persistent challenges — synthetic accessibility. Integrating Freedom Space 5.0 with exaScreen® combines the scale of 296 billion synthesizable compounds with Pharmacelera's algorithms, enabling accurate virtual screening across an ultra-large yet tractable chemical space. This combination gives researchers a truly powerful tool to identify novel, high-quality hits that would remain undiscovered with conventional libraries and screening approaches"

Olga Tarkhanova, PhD, CEO at Chemspace

“Leveraging the information contained in ultra-large chemical spaces through highly accurate 3D algorithms is key to accelerating and strengthening intellectual property in modern drug discovery. We are thrilled to collaborate with Chemspace to apply our accurate 3D QM- and ML-based algorithms to Freedom Space 5.0 , giving researchers access to a truly tractable and innovative chemical space”

Enric Gibert, PhD, CEO of Pharmacelera

About Chemspace

Chemspace is a global platform for discovering, designing, and delivering small molecules, providing integrated solutions for early-stage drug discovery through both online and offline platforms. The Chemspace online platform offers a comprehensive solution for molecule discovery, purchasing, and procurement, enabling exploration of trillions of small molecules. With customizable catalog access, flexible purchasing options, and advanced compound management tools, the platform delivers a streamlined experience from search to synthesis. The Chemspace offline platform provides end-to-end discovery services, including AI/ML-driven design, virtual screening, cheminformatics, chemistry, and biology services. This integrated approach supports hit identification, optimization, and biological validation within a coordinated workflow.

For more information, visit https://chem-space.com/search

About Pharmacelera

Pharmacelera is a deep-tech science-first company founded by experienced drug hunters, high-performance computing engineers, and leading academic researchers. The company has developed a proprietary in-silico platform that integrates accurate 3D Quantum-Mechanics (QM) models with advanced Artificial Intelligence (AI) algorithms to design novel, diverse, and high-quality molecules from ultra-large and previously untapped chemical spaces. Pharmacelera solutions provide access to its cutting-edge technology for HitID, H2L and LO.

Founded in 2015 and headquartered in Barcelona, Spain, Pharmacelera collaborates with leading pharmaceutical and biotech organizations across Europe and the United States.

Contact:

Chemspace
Olga Tarkhanova, Ph.D., CEO
o.tarkhanova@chem-space.com

Pharmacelera
Enric Gibert, Ph.D., CEO
contact@pharmacelera.com

The post Freedom Space 5.0 Integrates with exaScreen® to Enable 3D Ultra-Large Virtual Screening appeared first on Pharmacelera | Pushing the limits of computational chemistry.

]]> Pharmacelera Appoints Dr. Cynthia Tingle as Head of U.S. Operations and Business Development https://pharmacelera.com/blog/news/pharmacelera-appoints-dr-cynthia-tingle-as-head-of-us-operations-and-business-development/ Mon, 23 Feb 2026 22:35:16 +0000 https://pharmacelera.com/?p=15052 Boston and Barcelona — February 23, 2026 — Pharmacelera, a deep-tech company developing and applying high-accuracy Quantum Mechanics and Artificial Intelligence (“deep […]

The post Pharmacelera Appoints Dr. Cynthia Tingle as Head of U.S. Operations and Business Development appeared first on Pharmacelera | Pushing the limits of computational chemistry.

]]> Boston and Barcelona — February 23, 2026 — Pharmacelera, a deep-tech company developing and applying high-accuracy Quantum Mechanics and Artificial Intelligence (“deep physics”) algorithms to design therapies for unmet medical needs, today announced the appointment of Dr. Cynthia White Tingle as Head of U.S. Operations and Business Development.

Dr. Tingle holds a PhD in Organic Chemistry from Brown University and brings more than two decades of corporate and business development and customer success experience delivering advanced computing solutions to biopharma R&D and intellectual property teams. She has held senior leadership, commercial, and customer-facing roles at CambridgeSoft, CAS, Chemaxon, and Optibrium.

“Cynthia will play a pivotal role in advancing Pharmacelera’s growth strategy in the United States,” said Dr. Enric Gibert, CEO and Co-founder of Pharmacelera. “Her experience and leadership will be instrumental in building a strong US-based scientific team and expanding our collaborations with pharmaceutical companies, biotech firms, and research institutions across North America, always with a science-first and customer-focused approach”, he added.

“The integration of accurate Quantum Mechanics algorithms to model 3D molecular interactions with Artificial Intelligence methods capable of exploring ultra-large chemical spaces represents a meaningful step forward in strengthening intellectual property in drug discovery,” said Dr. Tingle. “Identifying novel and diverse active starting points is essential — but equally critical is the ability to progress them and design differentiated drug candidates”, she added.

The post Pharmacelera Appoints Dr. Cynthia Tingle as Head of U.S. Operations and Business Development appeared first on Pharmacelera | Pushing the limits of computational chemistry.

]]>